Abstract
BackgroundThe Janus Kinase (JAK) inhibitor Upadacitinib (UPA) has shown efficacy in rheumatoid arthritis (RA) in trials, yet real-world evidence is lacking.ObjectivesWe aimed to assess short-term effectiveness of UPA for standard...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
